AI Proteins, a Boston, MA-based biotechnology company, raised $18.2M in Seed funding.
The round was led by Cobro Ventures and Lightchain Capital.
The company intends to use the funds to expand operations and its business reach.
Led by CEO Drew Dennison and founder, President, and CSO Dr. Chris Bahl, AI Proteins is using its de novo protein design platform to unlock the therapeutic potential of miniproteins, which are peptides that form a hyperstable three-dimensional structure. Miniproteins can solve many issues facing traditional antibody development, acting to drive down costs, speed up therapeutic development, and improve success rates.